trial
as of 2026-07-01Relapse Prevention Study of Pimavanserin in Dementia-related Psychosis
NCTId NCT03325556
at a glance
Phase 3 · Completed
Enrollment 392 (actual)
Sponsored by ACADIA Pharmaceuticals Inc.
Primary completion 2019-07-31
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 3
Status
Completed
Enrollment
392 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Quadruple
Start
2017-09-27
Primary completion
2019-07-31
Eligibility
ALL · 50 Years · 90 Years
Interventions & indications
Sponsors
ACADIA Pharmaceuticals Inc.Lead Sponsor
Sites
83 total
Costa Mesa, United StatesFullerton, United StatesAventura, United StatesBoca Raton, United StatesMiami, United StatesMiami, United StatesMiami, United StatesNaples, United StatesOrlando, United StatesOrmond Beach, United StatesPompano Beach, United StatesWinfield, United States
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
392
Phase
PHASE3
Primary Completion Date
2019-07-31
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
company
indication